What is Biocept, Inc. (BIOC)?

Biocept, Inc. (BIOC) is a stock in the Healthcare sector, Medical - Diagnostics & Research industry. View full analysis on Stocks360.

What is the current price of BIOC?

The current price of BIOC is $0.43. Prices are updated in real time on Stocks360.

What is BIOC's price-to-earnings (PE) ratio?

BIOC's trailing twelve-month PE ratio is -0.01, based on current price and earnings per share data available on Stocks360.

What is BIOC's market capitalization?

BIOC's market capitalization is $450,786.00, placing it in the small-cap tier.

Biocept, Inc. (BIOC)

Stock analysis · NASDAQ · Healthcare · Medical - Diagnostics & Research

$0.43

Market Cap

$450.79K

PE (TTM)

-0.01

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.59

Day Range

$0.43 – $0.49

52-wk Range

$0.43 – $0.49

Avg Volume

N/A

Volume

572.52K

Biocept, Inc. (BIOC) is a publicly traded company in the Healthcare sector. Latest price: $0.43. Market cap $450.79K. Trailing PE -0.01. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Mar 29, 2023

EPS $-32.57 vs est. $-0.22

Missed by $32.35

Proprietary Signals

Signal snapshot temporarily unavailable.

About Biocept, Inc.

Biocept, Inc. is a company specializing in molecular diagnostics for cancer, primarily focused on developing and commercializing advanced diagnostic assays based on proprietary technology. These tests analyze circulating tumor cells (CTCs) and cell-free tumor DNA and RNA (ctDNA/ctRNA), primarily using standard blood samples. These assays furnish crucial insights to healthcare professionals, enabling them to identify specific genetic changes (oncogenic alterations) that qualify certain cancer patients for targeted therapies. This information is vital throughout the patient journey: at initial diagnosis, during disease progression, and for ongoing monitoring to detect the emergence of treatment resistance. Their diagnostic portfolio extends to various solid tumor types, including breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. Beyond blood-based diagnostics, Biocept offers specialized testing services for cerebrospinal fluid (CSF), analyzing tumor cells, ctDNA, and ctRNA. These services cater to a broad spectrum of medical specialists, such as medical oncologists, neuro-oncologists,…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.01×
P/S (TTM)	0.02×
P/B	0.03×
PEG	0.00×
P/FCF (TTM)	-0.03×
EV / EBITDA	0.01×
EV / Sales	-0.01×
Earnings Yield	-13055.50%
Free Cash Flow Yield	-3126.98%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$337.21K
Net Income (TTM)	-$58.85M
Free Cash Flow (TTM)	-$13.78M
Net Debt	-$788.00K
Working Capital	$10.84M
Gross Margin	-9.99%
Operating Margin	-123.69%
Net Margin	-124.09%
Return on Equity	-138.49%
Return on Invested Capital	-117.56%